Two payloads. One molecule. Now the data. In preclinical models, AVA6207 reversed TOP1i resistance and drove complete responses in resistant ovarian cancer and NSCLC models. Poster 161 today at #ENAsymp26 in Barcelona.
avacta.com/ava6207-overcomes…
#NEXTGENLOADING #AVCT
Dom Von Posen retweeted
Tiziana Life Sciences (Nasdaq: $TLSA ) presented today at the @Jefferies Global Healthcare Conference in London.
CEO Ivor Elrifi delivered a corporate overview and discussed our recent positive Phase 2a INFORM-MS topline results for intranasal foralumab in non-active secondary progressive multiple sclerosis (na-SPMS).
The presentation was well attended and highly engaging. We reviewed the trial’s dual primary endpoints, including a statistically significant reduction in microglial activation (p=0.0168) with the 50 μg dose versus placebo on TSPO-PET imaging, along with a favorable safety and tolerability profile, as well as clinically meaningful improvements in fatigue scores after just 12 weeks.
This data continues to generate significant attention across the MS and biotech communities. Thank you to everyone who joined us and to the Jefferies team for a great session.
#MultipleSclerosis #Biotech #JefferiesHealthcare #Foralumab #TLSA
In this Episode of the R&D Spotlight Series, the team discuss the key findings from our ESMO data. One important finding is that tumors recruit fibroblasts during treatment, leading to an increased ability to release the payload.
avacta.wistia.com/s/59m12mns… #AVCT
Dom Von Posen retweeted
$TLSA Tiziana Life Sciences to advance foralumab partnering talks at BIO-Europe 2026 tinyurl.com/27z5khea @tizianals #TLSA
Dom Von Posen retweeted
$TLSA Tiziana’s nasal foralumab reduces microglial activation in progressive MS trial tinyurl.com/2cgjqdne @tizianals #TLSA
Dom Von Posen retweeted
Tiziana (Nasdaq: $TLSA) KOL call highlights consistency between positive Phase 2a INFORM-MS topline results & longer-term benefits in expanded access program for intranasal foralumab in na-SPMS.
Key data:
• Significant ↓ microglial activation on TSPO-PET (50 μg, p=0.0168)
• Meaningful fatigue improvements (MFIS) at 12 weeks
• EDSS stabilization/improvement & no ADAs in EA program (up to 3 yrs)
Addressing a major unmet need in PIRA. Full analysis & FDA discussions ahead.
#MS #naSPMS #Biotech #Foralumab
tizianalifesciences.com/tizi…
Dom Von Posen retweeted
Lest we forget 🙏 “When you go home, tell them of us and say, For your tomorrow, we gave our today.”
Dom Von Posen retweeted
🔴 TYLKO U NAS! NOWE USTALENIA W SPRAWIE MICHAŁA O.
Po zamachu w Krakowie w sieci pojawiły się informacje sugerujące, że 24-latek mógł mieć związki ze skrajną prawicą.
Z nieoficjalnych ustaleń „Super Expressu”, potwierdzonych w kilku źródłach, wynika jednak, że Michał O. nie należał do żadnej prawicowej partii ani ekstremistycznej organizacji.
Służby miały dokładnie prześwietlić jego działalność w internecie i mediach społecznościowych. Według naszych informacji nie znaleziono tam śladów wskazujących na takie powiązania.
To nie oznacza jednak automatycznie wykluczenia radykalnych poglądów. Marcin Kierwiński mówił wcześniej, że pierwsze ustalenia wskazują na fascynację sprawcy ideologiami skrajnie prawicowymi.
Co dokładnie ustaliliśmy? 👇
polityka.se.pl/wiadomosci/sp…
Dom Von Posen retweeted
Tiziana (Nasdaq: $TLSA ) to host investor call with KOLs on positive Phase 2a INFORM-MS topline results for intranasal foralumab in na-SPMS:
• Statistically significant ↓ in microglial activation on TSPO PET (p=0.0168)
• Significant fatigue improvements in both dose arms after just 12 weeks
• Favorable safety & tolerability
Featuring Drs. Chitnis, Singhal & Weiner
Monday, Nov 9 | 12pm ET / 5pm GMT
Register: edge.media-server.com/mmc/p/…
#MS #Biotech #TLSA
Full PR: tizianalifesciences.com/tizi…
1/21 $TLSA closed at $0.67 today, down 16.2% on 2.8m shares, despite positive INFORM-MS topline results. Like many shareholders, I'm extremely disappointed. I think today's reaction reflects clinical nuance, poor communication and financing fears. A thread.
20/21 My criticism remains: $TLSA communications failed shareholders before Toronto, and today's release offered no apology or explanation for the missed timetable. It recalls its London-listed days. Scientific progress and respect for investors should coexist.
1
4
189
21/21 I have no crystal ball. My theory is today's -16.2% was a mix of clinical uncertainty, financing anxiety, speculative trading and possible automated selling—not proof of a leak or failed science. We live to fight another day. Good luck to all $TLSA shareholders.
3
8
172










